For startups adopting AI, the most effective starting point is not a massive overhaul. Instead, focus on a single, high-value process unit like a bioreactor. Use its clean, organized data to apply simple predictive models, demonstrate measurable ROI, and build organizational confidence before expanding.

By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.

The increasing volume of new therapies requires pharma companies to stop treating each launch as a unique event. Instead, they must develop a scalable, repeatable, and excellent launch capability to handle the future pipeline efficiently and consistently.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

To ensure a smooth transition from development to production, an operations or manufacturing SME must be part of the design process from the start. Otherwise, products are developed without manufacturability in mind, leading to expensive, reactive fixes and subjective quality control during scale-up.

CEO Marc Salzberg clarifies that for their recombinant protein, the difficulty was not in the manufacturing itself but in designing the complex upstream process, purification, and analytics. This innovation became a core asset and "claim to fame," allowing them to transfer a well-defined process to a capable CDMO for scaling.

Early CMC decisions for Phase 1 clinical supply are foundational. Certain errors made at this stage, such as failing to prove cell bank clonality, are irreversible and can jeopardize the entire development program, similar to a faulty foundation in a house.

A 'healthy tension' exists between research teams, who want to continually iterate on a therapy's design, and manufacturing teams, who need a finalized process to scale production for trials. Knowing precisely when to 'lock down' the design is a critical, yet difficult, decision point for successful commercialization.

Resolution Therapeutics' CEO warns that manufacturing process changes cannot wait for pivotal trials in cell therapy. The drug product used in a Phase 1/2 study must be highly comparable to the final commercial version to avoid extremely costly delays and extensive comparability studies later in development.